Background: People who inject drugs (PWID) are overrepresented in the HCV-infected community. Past Canadian guidelines do not advocate HCV treatment of HIV co-infected PWID, fearing reduced ÃâÃÅ¾ÃâÃÂ¸cÃâÃâcy and recurrent viremia ÃâÃâÃâ¦ÃÅÃâÃÅ¾r successful treatment, due to ongoing risk behaviours. These factors may be more prominent among those co-infected with HIV.
Methods: A Retrospective chart review analysis was performed to identify HIV/HCV co-infected individuals who actively injected drugs within 6 months preceding or during HCV treatment. Information regarding Ãâ Ãâ°ÃâÃâÃâ ÃÅ¸ÃâÃÅ¾nÃâ ÃÅ¡ cÃâ¦ÃÅ¡ÃâÃârÃâÃâcÃâ ÃÅ¡ÃâÃÅ¾rÃâ¦ÃÂÃâ ÃÂÃâ ÃÅ¸cÃâ ÃÂÃÂÃâ¢ risk behaviours, HCV treatment, and virologic follow-up post-treatment was collected.
Results: We identified 45 HIV/HCV co-infected PWID (mean age 51.9 years, 6.7% female, 57.8% on opiatesubstitution therapy, 66.7% genotype 1, 82.2% treatment naïve, 73.3% on interferon-based therapies, and 1.52 person years of follow-up/subject). Following successful HCV therapy, 3 cases of HCV recurrent viremia were identified
Conclusion: HCV Ãâ¦ÃÂnÃâÃÂ¨ÃâÃÅ¾cÃâ ÃÅ¸Ãâ¦ÃÂ½n can be successfully treated in high-risk HIV co-infected individuals. In our unique Ãâ ÃÂÃâÃÅ¾Ãâ ÃÂ«nÃâ¦ÃÂÃÂÃâ¢ few cases of recurrent viremia were identified in mediumterm follow-up.
Tyler Raycraft , Syune Hakobyan , Sahand Vafadary , Arshia Alimohammadi , Ghazal Kiani , Jay Shravah , Rajvir Shahi and Brian Conway